CRB0017 is a novel anti-ADAMTS-5 monoclonal antibody (mAb) intended for therapeutic use as a disease-modifying osteoarthritis drug (DMOAD).
ADAMTS-5, or aggrecanase-2, is the main enzyme that causes degradation of aggrecan, a key component of cartilage matrix structure and joint function, and it is strongly implicated in the pathogenesis of osteoarthritis.
CRB0017 has a novel mode of action in that it specifically targets the spacer domain of human ADAMTS-5. CRB0017 is effective in three clinically relevant experimental models of osteoarthritis progression:
- STR/ort mouse, which develops a spontaneous disease closely matching human osteoarthritis
- Destabilization of the Medial Meniscus (DMM) in C57 BL6J mice, the model originally used to validate ADAMTS-5 as a main target for osteoarthritis therapy
- Medial Meniscal Tear (MMT) in rats.
CRB0017 is currently under preclinical development.